$1.14
+0.00 (+0.00%)
Open$1.15
Previous Close$1.14
Day High$1.21
Day Low$1.11
52W High$49.35
52W Low$22.96
Volume—
Avg Volume451.9K
Market Cap29.97M
P/E Ratio33.03
EPS$1.18
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+4,018.4% upside
Current
$1.14
$1.14
Target
$46.95
$46.95
$33.28
$46.95 avg
$64.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 47.89M | 42.94M | 46.10M |
| Net Income | 949.8K | 770.7K | 699.4K |
| Profit Margin | 2.0% | 1.8% | 1.5% |
| EBITDA | 1.44M | 1.43M | 1.37M |
| Free Cash Flow | 717.1K | 500.4K | 604.2K |
| Rev Growth | -0.9% | +8.9% | +4.5% |
| Debt/Equity | 0.33 | 0.39 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |